Kinnari Patel - May 14, 2024 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
President, Head of R&D and Chief Operating Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Kinnari Patel
Stock symbol
RCKT
Transactions as of
May 14, 2024
Transactions value $
-$94,474
Form type
4
Date filed
5/20/2024, 04:26 PM
Previous filing
Feb 21, 2024
Next filing
Aug 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Options Exercise $0 +3.99K +1.37% $0.00 296K May 14, 2024 Direct F1
transaction RCKT Common Stock Options Exercise $0 +5.55K +1.87% $0.00 302K May 14, 2024 Direct F2
transaction RCKT Common Stock Other $0 +12K +3.97% $0.00 314K Feb 14, 2022 Direct F1, F3
transaction RCKT Common Stock Other $0 +52.5K +16.73% $0.00 366K Aug 12, 2022 Direct F3, F4
transaction RCKT Common Stock Other $0 +38.7K +10.58% $0.00 405K Feb 14, 2023 Direct F2, F3
transaction RCKT Common Stock Sale -$94.5K -4.05K -1% $23.35 401K May 16, 2024 Direct F5
holding RCKT Common Stock 5.68K May 14, 2024 By Spouse
holding RCKT Common Stock 105K May 14, 2024 By Adaptive Technology LLC F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Restricted Stock Units Options Exercise $0 -3.99K -25% $0.00 12K May 14, 2024 Common Stock 3.99K Direct F1, F7
transaction RCKT Restricted Stock Units Options Exercise $0 -5.53K -12.5% $0.00 38.7K May 14, 2024 Common Stock 5.53K Direct F2, F7
transaction RCKT Restricted Stock Units Other $0 -12K -100% $0.00* 0 Feb 14, 2022 Common Stock 12K Direct F1, F3, F7
transaction RCKT Restricted Stock Units Other $0 -52.5K -100% $0.00* 0 Aug 12, 2022 Common Stock 52.5K Direct F3, F4, F7
transaction RCKT Restricted Stock Units Other $0 -38.7K -100% $0.00* 0 Feb 14, 2023 Common Stock 38.7K Direct F2, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.
F3 Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.
F4 Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025.
F5 The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
F6 The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.
F7 Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

President, Head of R&D and Chief Operating Officer